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Background: In more than 70% of families with a strong history of breast and ovarian cancers, pathogenic
mutation in BRCA1 or BRCA2 cannot be identified, even though hereditary factors are expected to be involved. It
has been proposed that tumors with similar molecular phenotypes also share similar underlying pathophysiological
mechanisms. In the current study, the aim was to investigate if global RNA profiling can be used to identify
functional subgroups within breast tumors from families tested negative for BRCA1/2 germline mutations and how
these subgroupings relate to different breast cancer patients within the same family.
Methods: In the current study we analyzed a collection of 70 frozen breast tumor biopsies from a total of 58
families by global RNA profiling and promoter methylation analysis.
Results: We show that distinct functional subgroupings, similar to the intrinsic molecular breast cancer subtypes,
exist among non-BRCA1/2 breast cancers. The distribution of subtypes was markedly different from the distribution
found among BRCA1/2 mutation carriers. From 11 breast cancer families, breast tumor biopsies from more than one
affected family member were included in the study. Notably, in 8 of these families we found that patients from
the same family shared the same tumor subtype, showing a tendency of familial aggregation of tumor subtypes
(p-value = 1.7e-3). Using our previously developed BRCA1/2-signatures, we identified 7 non-BRCA1/2 tumors with a
BRCA1-like molecular phenotype and provide evidence for epigenetic inactivation of BRCA1 in three of the tumors.
In addition, 7 BRCA2-like tumors were found.
Conclusions: Our finding indicates involvement of hereditary factors in non-BRCA1/2 breast cancer families in which
family members may carry genetic susceptibility not just to breast cancer but to a particular subtype of breast
cancer. This is the first study to provide a biological link between breast cancers from family members of high-risk
non-BRCA1/2 families in a systematic manner, suggesting that future genetic analysis may benefit from subgrouping
families into molecularly homogeneous subtypes in order to search for new high penetrance susceptibility genes.
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Breast cancer is the most common malignant disease and
the leading cause of cancer death among women [1]. It is
estimated that approximately 5-10% of all breast cancers
have a strong hereditary component. High-risk families
often show an apparently dominant inheritance pattern of
breast cancer cases and are often characterized by early
age of onset and presence of ovarian cancers, bilateral
breast cancers, and male breast cancers. Germline muta-
tions in BRCA1 and BRCA2 only explain the breast can-
cer risk in approximately one fourth of these families,
however, it is expected that additional BRCA1/2 muta-
tions still remain undetected by the screening methods
used today [2,3].
Despite intensive research, genetic linkage analysis,
genome-wide association studies (GWAS) and most re-
cently next generation sequencing (NGS) exome studies
have failed to identify other common high penetrance
breast cancer susceptibility genes, like BRCA1 and
BRCA2, and it is now generally accepted that no single
high penetrance gene is likely to account for a larger
fraction of the remaining familial aggregation [4-9]. In-
stead, the remaining genetic susceptibility is expected to
be explained by a mixture of rare high-risk variants and
polygenic mechanisms involving more common and/or
rare low-penetrance alleles or rare moderate penetrance
genes, acting in concert to confer a high breast cancer
risk [3,10,11]. Furthermore, a fraction of the familial ag-
gregation of breast cancer cases may be explained by
sharing of common environmental risk factors and ex-
ogenous hormone use, or be just random aggregation of
sporadic breast cancers.
Several rare inactivating mutations in other high pene-
trance genes have been described to contribute to an in-
creased breast cancer risk, such as TP53, CDH1, PTEN,
STK11, RAD51C, and RAD51D and in the low/moderate
penetrance genes ATM, CHEK2, BRIP1, and PALB2
among others (reviewed by Vargas et al. [12]). Most are
involved in the maintenance of genomic integrity and
DNA repair mechanisms and many are associated with
multiple cancer syndromes. However, these only explain
a minor fraction of the remaining breast cancer risk,
leaving the etiology of the remaining high-risk families
unexplained. This results in less optimal genetic coun-
seling and risk reducing options for healthy members in
these families. It is therefore highly important to identify
the cancer predisposition defects of the unsolved high-
risk non-BRCA1/2 families.
The histopathologic characteristics of BRCA1 and
BRCA2 breast tumors are well described. BRCA1 tumors
are frequently grade 3, estrogen receptor (ER) negative,
progesterone receptor (PR) negative and HER2-negative
(triple-negative), while the majority of BRCA2 tumors
are grade 2/3, ER-positive and HER2-negative [13].Contrary, familial non-BRCA1/2 breast cancers have
been shown to be a very heterogeneous group with va-
ried histopathologic features [14,15].
Gene expression profiling studies of sporadic/unselected
breast cancers have revealed the existence of at least five
clinically relevant subgroups: basal-like, HER2-enriched,
luminal A (lumA) and luminal B (lumB) [16-21]. The mo-
lecular subtypes correspond broadly to known histopa-
thological characteristics and are associated with different
clinical outcomes. Basal-like cancers are mostly high-
grade, triple-negative tumors with high expression of
basal epithelial markers such as CK5/14/17; while HER2-
enriched cancers are associated with amplification of the
HER2-gene. LumA cancers are typically low-proliferative,
ER + tumors while lumB are high-proliferative, ER + can-
cers. Luminal cancers show high expression of luminal-
associated genes such as CK8/18. In addition to these
four subtypes, a normal-like subtype has also been iden-
tified which exhibit high similarity with normal breast
epithelium.
Only few gene expression profiling studies of heredi-
tary breast cancers have been published. Recently, we
and others have shown that BRCA1 mostly are basal-like
while the majority of BRCA2 tumors are of luminal sub-
types [22-24]. Non-BRCA1/2 cancers have been reported
to be distributed across the different molecular subtypes
similar to the sporadic cancers; though several studies
indicate an enrichment of the lumA subtypes among
non-BRCA1/2 tumors compared to sporadic/unselected
cases [22,23,25].
Because of the underlying genetic heterogeneity of
the non-BRCA1/2 families, the search for more high-
susceptibility genes is particular complicated. Even though
promising technologies such as exome sequencing pro-
vides new opportunities, such attempts have so far failed
to identify new high-susceptibility genes [7-9]. The recent
negative results using exome sequencing indicate that in-
telligent stratification is needed in order to reduce hetero-
geneity. One possible approach to reduce heterogeneity
could be to pre-select cases based on molecular tumor
characteristics.
In the present study, we have used genome-wide RNA
profiling analysis for molecular characterization of familial
non-BRCA1/2 tumors. It has been proposed that tumors
with similar molecular characteristics are a result of simi-
lar pathophysiological mechanisms. Thus, stratifying pa-
tients by molecular tumor subgroups based on RNA
profiles could potentially facilitate the identification of
new breast cancer susceptibility genes by increasing the
statistical power of linkage analysis, genome-wide asso-
ciation, or exome sequencing studies. Here, we studied
how RNA profiling can be used to identify functional sub-
groups within tumors from familial non-BRCA1/2 breast
cancers and to what extent these subgroupings relate to
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viously developed gene signatures were applied to identify
tumors with BRCA1-like and BRCA2-like phenotypes
within the group of non-BRCA1/2 tumors.
Methods
Ethics statement
The study was carried out as a retrospective register study
and in accordance with the Helsinki Declaration. The
study has been approved by The National Committee on
Health Research Ethics of Denmark (S-VF-20020142),
waiving the requirement for informed consent for the
study.
Patient material
The study was performed on frozen primary breast tumor
samples collected from 1982 to 2008. Samples were ob-
tained from the tumor biobanks of Dept. of Pathology,
Odense University Hospital and Danish Breast Cancer
Cooperative Group (DBCG). Breast tumor tissue from
125 patients with germline mutations in BRCA1 (n = 33)
or BRCA2 (n = 22) or with no detectable germline muta-
tion in BRCA1 or BRCA2 (n = 70) were included in the
study. During the period from 2000 to 2005 (64% of the
included patients) genetic mutation screening were con-
ducted using a setup consisting of denaturing high-
performance liquid chromatography (DHPLC), protein
truncation test (PTT) and Sanger sequencing analysis in
addition to Multiplex Ligation-dependent Probe Ampli-
fication (MLPA) for detection of larger copy number
abnormalities. From 2006 (36% of the included patients),
the DHPLC method were replaced by Temperature
Gradient Capillary Electrophoresis (TGCE) for prescree-
ning of small exons. The patients were all part of a family
referred to genetic counseling (Dept. of Clinical Genetics,
Odense University Hospital or Dept. of Clinical Genetics,
Rigshospitalet) because of a family history of breast can-
cer. The families were recruited in the period from 2003
to 2009. Inclusion criteria were 1) a pedigree indicating
autosomal dominant inheritance of a breast cancer predis-
position or 2) presence of ovarian cancer in a pedigree
with breast cancer cases or 3) a very young age at diagno-
sis of breast cancer (before 35 years). A three generation
pedigree was constructed on all families depending on the
information available from the families. All cancer diag-
noses were confirmed by hospital records, histopathology
reports or death certificates. Serving as a representative
control group, primary breast tumor samples (n = 128)
were randomly selected among available samples origina-
ting from the same department and time period as for the
hereditary samples. The family histories of the control pa-
tients were unknown, but none of the patients had been re-
ferred to genetic counseling at Odense University Hospital,
from where the vast majority of patients were recruited,and are therefore here referred to as sporadic. We have
previously described gene expression analyses of a subset
of the included tumors (BRCA1, BRCA2 and sporadic
cases) [24]. Tumor and patient characteristics are summa-
rized in Table 1. Characteristics of the included families are
summarized in Table 2.Histopathological review
Samples included in the study contained at least 50%
tumor cells determined by representative hematoxylin-
eosin stainings. Tumor samples were macro-dissected
to increase purity and remove normal cell-enriched
areas. Histopathological data and ER, PR, and HER2 sta-
tus determined by immunohistochemistry (IHC) were
obtained from DBCG. In addition, gene-expression data
were used to determine ER, PR, and HER2 status as pre-
viously described [24].Gene expression analysis
Gene expression analysis was performed using a custo-
mized version of Agilent SurePrint G3 Human GE
8x60K Microarray and raw data were pre-processed as
previously described [24]. Microarray data have been de-
posited to the Gene Expression Omnibus (GSE49481).Detection of promoter methylation
Hypermethylation of the BRCA1 and BRCA2 promoter
regions were determined by the methylation-specific
MLPA kit ME001C (MRC-Holland) using DNA ex-
tracted from freshly frozen tumor tissue. Blood DNA
from 6 healthy donors were used as reference. CpGe-
nome Universal Methylated DNA (Millipore) was used
as positive control. A methylation ratio > 0.2 was con-
sidered as positive promoter methylation. Methylation
status was successfully determined in 235 out of the 253
samples analyzed by gene expression analysis.Data analysis
Unsupervised methods
Unsupervised hierarchical clustering (Euclidian metric,
complete linkage) and principal-component analysis
(PCA) were carried out in Qlucore Omics Explorer.
Expression levels of each gene had been standardized to
zero mean and unit variance.Molecular subtype classification
PAM50 subtype classifier described by Parker et al. was
used to classify tumors into five intrinsic molecular sub-
types using the R package genefu [20]. Probes for all 50
PAM50 genes were present on the Agilent microarray
used.
Table 1 Patient and tumor characteristics
non-BRCA1/2 (n = 70) BRCA1 (n = 33) BRCA2 (n = 22) Sporadic (n = 128)
Estrogen receptor
ER+ 8.6% 42.4% 90.9% 83.6%
ER- 21.4% 57.6% 9.1% 16.4%
Progesterone receptor
PR+ 65.7% 21.2% 72.7% 61.7%
PR- 34.3% 78.8% 27.3% 38.3%
HER2 status
HER2+ 14.3% 9.1% 4.5% 16.4%
HER2- 85.7% 90.1% 95.5% 83.6%
Lymph node
LN+ 41.4% 45.5% 63.6% 39.8%
LN- 52.9% 48.5% 31.8% 58.6%
NA 5.7% 6.1% 4.5% 1.6%
Tumor size
Mean tumor size, mm [±SD] 25 [±18] 23 [±10] 25 [±13] 25 [±16]
Histologic grade
Grade 1 17.1% 9.1% 9.1% 25.0%
Grade 2 40% 21.2% 50.0% 37.5%
Grade 3 28.6% 54.5% 31.8% 22.7%
NA 14.3% 15.2% 9.1% 14.8%
Tumor type
Invasive ductal carcinoma 78.6% 84.8% 86.4 % 82.0%
Invasive lobular carcinoma 12.9% 3.0% 9.1 % 9.4%
Mucinous carcinoma - - - 1.6%
Medullary carcinoma 1.4 % 6.1% - 0.8%
Tubular carcinoma - - - 2.3%
Metaplastic carcinoma 1.4 % - - -
Other - 6.1 % - 1.6%
NA 5.7 % - 4.5% 2.3%
Age
Median age, years [range] 50 [29–86] 42 [25–74] 43.5 [28–72] 61 [27–95]
< 50 years 47.1% 63.6% 68.2% 16.4%
≥ 50 years 52.9% 36.4% 31.8% 83.6%
Menupause status
Premenopausal 52.9% 60.6% 68.2% 23.4%
Perimenopausal 2.9% - 4.5% 11.7%
Postmenopausal 38.6% 36.4% 22.7% 60.9%
Other 2.9% - - 1.6%
NA 2.9% 3.0% 4.5% 2.3%
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Aggregation of breast cancer subtypes in the observed
families was tested using computer simulation. In the
simulation, the observed tumor samples were randomly
assigned to each family with the number of assignedtumors as observed in the family. The counts for tumor
subtypes falling into each family were recorded. The
procedure was repeated for 100,000 times based on
which the empirical p-value for testing familial aggrega-
tion of a tumor subtype was calculated as the proportion
Table 2 Summarized characteristics of the non-BRCA1/2
families (n = 58)
Percentage
Breast c. + ovarian c. 36%
2 Breast c. 33%
3 Breast c. 24%
>3 Breast c. 26%
Bilateral breast c. 29%
Early onset breast c. (< 35 years) 10%
Male breast c. 2%
Prostate c. 17%
Colon c. 19%
Cervical c. 14%
Rectal c. 14%
Malignant melanoma 12%
Ventricular c. 12%
Other cancers 52%
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more tumors of the same subtype.
A microarray gene expression dataset published by
Hedenfalk et al. was used for confirmative assessment of
familial aggregation of molecular breast cancer subtypes
[26]. Pre-processing steps of the dataset are described in
the supplementary information (see Additional file 1:
Methods S1).
Prediction of BRCA1 and BRCA2 associated breast cancers
Two subtype specific gene signatures have previously been
developed by our group using the included BRCA1,
BRCA2 and sporadic samples [24]. Using the 110-gene
basal BRCA1 signature, we were able to distinguish
BRCA1 from sporadic tumors among basal-like samples
and the 100-gene lumB BRCA2 signature enabled us to
separate BRCA2 tumors from sporadic among lumB sam-
ples, both with high accuracies. Here, we used the gene
signatures, employing the support vector machines algo-
rithm (linear kernel), to identify tumors with BRCA1-like
and BRCA2-like phenotype within basal-like and lumB
non-BRCA1/2 tumors, respectively.
Results
Pathological characteristics of patient material
In the present study, frozen primary breast tumor sam-
ples were collected from 70 non-BRCA1/2, 33 BRCA1,
22 BRCA2, and 128 sporadic cases. Median age of diag-
nosis was 50 years for the non-BRCA1/2 patients com-
pared to 42 years (BRCA1) and 43.5 years (BRCA2) for
mutation carriers and 61 years for sporadic cancer pa-
tients. Tumor and patient characteristics are summa-
rized in Table 1. The majority of BRCA1 tumors wereER- (58%) and tumor grade 3, while BRCA2 tumors
were predominantly ER + (91%) and grade 2 or 3. Tumor
grades of non-BRCA1/2 tumors were distributed more
evenly, but compared to sporadic tumors, overall slightly
higher. Of the non-BRCA1/2 tumors, 17% displayed
triple-negative phenotype (ER-/PR-/HER2-), compared
to 8% of sporadic tumors, 55% of BRCA1 tumors, and
9% of BRCA2 tumors.
Subgroups within non-BRCA1/2 tumor samples are
predominantly determined by ER status and molecular
subtypes
Genome wide gene expression analyses resulted in a data
set consisting of 22,171 probes with unique gene symbols
assigned. We performed unsupervised two-dimensional
hierarchical clustering analysis of the whole series of
tumors available (70 non-BRCA1/2, 33 BRCA1, 22 BRCA2
and 128 sporadic) using the 500 most variant genes
(Figure 1). Two main branches were formed, separating
ER- samples from ER + samples. The ER- cluster could be
further subdivided into a triple-negative cluster, covering
the majority of the BRCA1 tumors, a HER2+/ER-/PR-
cluster and a smaller mixed cluster. Tumors were clas-
sified into the intrinsic molecular subtypes (basal-like,
lumA, lumB, HER2-enriched, or normal-like) by the
PAM50 classifier developed by Parker et al. [20]. The
triple-negative cluster consisted of only basal-like tumors,
while the majority of HER2-enriched tumors were found
in the HER2+/ER-/PR- cluster. Within the ER +main
cluster, sub-branches enriched for lumA and lumB
samples were present. 13/22 BRCA2 and 8/12 ER +
BRCA1-associated tumors grouped in the lumB branches.
Non-BRCA1/2 and sporadic tumors were not confined to
any specific subcluster.
Clearly, hormone receptor status and molecular sub-
types were the major determinants of the structure of the
hierarchical clustering when including the whole series of
samples. To clarify to what extent clustering of non-
BRCA1/2 tumors were influenced by the presence of the
BRCA1, BRCA2 and sporadic tumors, hierarchical cluster-
ing analysis was conducted using only data from non-
BRCA1/2 tumor samples (Additional file 2: Figure S1).
The clustering pattern of non-BRCA1/2 was found to be
comparable to the initial clustering analysis, again pre-
dominantly associated with hormone receptor status and
molecular subtypes.
The distribution of the PAM50 classified intrinsic mo-
lecular subtypes within non-BRCA1/2, BRCA1, BRCA2
and sporadic tumors was determined (Figure 2, Additional
file 3: Figure S2, Additional file 4: Table S1). All five mo-
lecular subtypes were found within the non-BRCA1/2
tumor class. The majority of non-BRCA1/2 tumors were
mainly classified as lumA (33/70, 47%) or lumB (18/70,
26%), while 9 tumors were basal-like (13%), 7 HER2-
Figure 1 Hierarchical clustering of 253 breast tumor samples using the 500 most variant genes across all samples. In the heat map rows
correspond to genes and columns to samples. Red indicates elevated expression, green reduced expression. Status bars designate molecular
subtype, hormone receptor status and sample group.
Larsen et al. BMC Medical Genomics 2014, 7:9 Page 6 of 13
http://www.biomedcentral.com/1755-8794/7/9enriched (10%) and 3 were normal-like (4%). The distri-
bution of molecular subtypes among the non-BRCA1/2
tumors was similar to the distribution found in the
sporadic tumors; although a tendency towards more non-
BRCA1/2 tumors were basal-like while fewer were clas-
sified as lumB. On the contrary, non-BRCA1/2 tumors
were markedly different from both BRCA1 and BRCA2
tumors which were highly associated with the basal-like
subtype (p = 1.2 × 10-6, Fisher’s exact test) and lumB sub-
type (p = 1.2 × 10-4, Fisher’s exact test), respectively.
BRCA-like tumors can be identified among non-BRCA1/2
tumors
We have previously developed two subtype specific gene
signatures, a 110-gene basal BRCA1 signature and a100-gene lumB BRCA2 signature [24]. These signatures
were here used to predict BRCA1 and BRCA2 asso-
ciation among basal-like and lumB non-BRCA1/2 tu-
mors, respectively (Figure 3). Seven basal-like tumors
out of nine were classified as BRCA1-like (78%) and the
remaining 2 as sporadic-like (22%). Among the lumB
subtype, 7 samples were classified as BRCA2-like (39%)
and 11 as sporadic-like (61%). Detailed prediction results
can be found in Additional file 5: Table S2.
Epigenetic inactivation of BRCA1 by promoter
methylation
To identify aberrant methylation patterns in BRCA1 and
BRCA2 promoter regions, tumor tissues were analyzed
using the ME001C methylation-specific MLPA kit
Figure 2 Association between hereditary breast cancers and
molecular subtypes. Distribution of molecular subtypes among
familial non-BRCA1/2, BRCA1, BRCA2 and sporadic breast cancer samples.
Tumors were classified into molecular subtypes using the PAM50
classifier. The molecular subtypes of the BRCA1, BRCA2 and sporadic
breast cancer samples have been described previously in Larsen et al.
[24]. Numbers in brackets refer to number of samples in each group.
Figure 3 Prediction of BRCA1 and BRCA2 association among familial n
to predict BRCA1 and BRCA2 association among basal-like and lumB non-BR
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obtained from all 33 BRCA1 tumors, 18 out of 22 BRCA2
tumors, 64 out of 70 non-BRCA1/2 tumors and 120 out
of 128 sporadic tumors. Six samples were found to be
positive for methylation of the BRCA1 promoter, counting
three basal-like non-BRCA1/2 tumors, one normal-like
non-BRCA1/2 tumor, one basal-like sporadic tumor and
one lumB sporadic tumor. Notably, the three basal non-
BRCA1/2 tumors classified as BRCA1-like were all found
to have BRCA1 promoter hypermethylation. None of the
cases showed methylation of the BRCA2 promoter.
Methylation of the BRCA1 promoter was associated
with a significant reduction of the BRCA1 mRNA ex-
pression level compared to tumors not methylated in
the BRCA1 promoter (p = 0.024, t-test, Additional file 6:
Figure S3). Notably, four out of the 6 methylated sam-
ples exhibited extremely low BRCA1 expression com-
pared to the remaining non-methylated samples.
Molecular subtypes aggregates within non-BRCA1/2
families
The 70 non-BRCA1/2 patients included in the study origi-
nated from 58 breast and/or ovarian cancer families tested
negative for germline mutations in BRCA1 or BRCA2.
From 10 of these families, breast tumor biopsies were
available from two affected family members and from a
single family we obtained tumor material from three pa-
tients. The pedigrees of these eleven families are shown in
Figure 4, along with corresponding molecular subtypes,
BRCA1 methylation status and prediction results obtained
by the basal BRCA1-classifier and the lumB BRCA2-classi-
fer. In 8 of the families we found that affected members of
the same family shared the same tumor subtype. Three
families were characterized by only lumA tumors, 3 fa-
milies had only lumB tumors, 1 family contained only
HER2-enriched tumors, and 1 family only basal-like tu-
mors (Table 3).on-BRCA1/2 tumors. Subtype specific gene signatures were applied
CA1/2 tumors, respectively.
Figure 4 Pedigrees of 11 selected non-BRCA1/2 families included in this study. Molecular subtypes determined by the PAM50 classifier and
positive BRCA1 promoter methylation are visualized. For basal-like and lumB tumors, the result of the prediction of BRCA1 and BRCA2 association
are given. If available, IHC ER status is indicated from family members not analyzed in this study.
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Table 3 Subtype classification of tumors from 11 families with tumor material from more than one affected individual
FamilyID Basal-like HER2-enriched Luminal A Luminal B Normal-like
031 2 - - - -
018 - 2 - - -
017 - - 2 - -
029 - - 3 - -
042 - - 2 - -
024 - - - 2 -
030 - - - 2 -
034 - - - 2 -
027 1 - - 1 -
006 - - 1 - 1
014 - - 1 1 -
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formed familial aggregation testing using computer si-
mulation as described in Materials and Methods. The
result of the simulation study confirmed that the degree
of familial subtypes aggregation was significant, non-
random aggregation (p-value = 1.7e-3).
In order to confirm the observed tendency in indepen-
dent samples, we used a dataset published by Hedenfalk
et al. [26]. This dataset contained gene expression profiles
for tumors of 16 non-BRCA1/2 individuals, belonging to 8
different families. From five families, two or three tumors
were analyzed, in total 12 samples. Subtype prediction was
carried out by the PAM50 classifier (Table 4). Even though
only 19 of the 50 probes were present in the Hedenfalk
dataset, the same tendency was observed here. In 3 two-
case families, members from the same family shared the
same tumor subtypes, whereas in one family 2 normal-like
tumors and one basal-like tumor were found, and another
family had three different subtypes. Simulation analysis
confirmed that the degree of familial aggregation was sig-
nificant (p-value = 0.017).
Discussion
In this report, we investigated genome-wide RNA pro-
files of tumors from familial breast cancer cases where
no BRCA1 or BRCA2 mutations could be identified by
traditional genetic analysis for germline mutations. The
search for high-susceptibility genes that can explain
the breast cancer risk in the remaining non-BRCA1/2Table 4 Subtype classification of tumors from Hedenfalk et a
FamilyID Basal-like HER2-enriched
L101 2 -
L414 - -
L505 - -
L99 1 -
L16 1 1families is complicated by their underlying genetic hetero-
geneity, and a probable explanation of the low success rate
of attempts to identify new high-risk alleles. Obviously, in-
telligent stratification of cases is needed in order to reduce
this heterogeneity. The aim of this study was to explore if
RNA profiling can be used to identify homogeneous sub-
groups among these families. Subgrouping into homoge-
neous subsets could be of considerable value for further
genetic analysis and may facilitate the identification of
new high penetrance breast cancer susceptibility genes.
Here we describe RNA based subgroupings among non-
BRCA1/2 breast tumors, displaying strong associations
with the previously described intrinsic molecular subtypes.
Within these subgroups we identified tumors with BRCA1-
like and BRCA2-like molecular phenotype. Furthermore,
we showed that breast cancer family members from the
same family often show identical molecular subtypes.
Molecular subtypes of familial non-BRCA1/2 tumors
Unsupervised hierarchical clustering was used to reveal
overall patterns and for identification of subgroups within
the familial non-BRCA1/2 tumors. The clustering dis-
played a high level of heterogeneity with sub-branches
mainly related to hormone receptor status and the intrin-
sic molecular tumor subtypes. Comparable subgroupings
were observed when including a set of 33 BRCA1, 22
BRCA2 and 128 sporadic tumors from our previous study
[24]. Here, familial non-BRCA1/2 tumors clustered with
tumors from sporadic and with BRCA germline mutationl
Luminal A Luminal B Normal-like
- - -
2 - -
- 2 -
- - 2
1 - -
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mors are very similar to the intrinsic molecular subtypes
found among sporadic/unselected breast cancers [16,17].
Similar observations have been described by others using
gene expression analysis and immunohistochemical surro-
gate markers for subtype classification [15,25,27-29].
In our study, familial non-BRCA1/2 tumors classified
predominantly as luminal subtype with lumA tumors ac-
counting for almost half of the tumors. The distribution
of subtypes was very similar to the distribution found
among sporadic tumors. Only few studies have investi-
gated molecular subtypes with relation to familial non-
BRCA1/2 tumors [22,23,25]. Jönsson et al. and Waddell
et al. reported that lumA tumors were the most pre-
dominant luminal subtype among familial non-BRCA1/2
tumors, similar to what we observed in our study group,
while Nagel et al. reported that lumB tumors were most
frequent. These variations were however minor and
might be due to differences in the inclusions criteria and
subtyping methodologies used.
Identification of BRCA-like tumors among familial
non-BRCA1/2 tumors
BRCA1 and BRCA2 mutation screening technology tra-
ditionally include Sanger sequencing in combination with
MLPA analysis. However, a fraction of mutations will still
not be detected. We used a basal BRCA1 signature from
our previous study to predict whether tumors with a
BRCA1-like molecular phenotype were present among
basal non-BRCA1/2 samples [24]. We found that 7/9
(78%) basal non-BRCA1/2 samples were BRCA1-like. In a
similar approach using our lumB BRCA2 signature, we
identified 7/18 (39%) lumB non-BRCA1/2 tumors to be
BRCA2-like. This could indicate a BRCA1/2-deficiency in
these tumors, either caused by an inactivating mutation
not detected by current technology or epigenetic silencing
such as promoter hypermethylation of the BRCA1/2 genes
or other susceptibility genes in the same pathway.
A similar approach was used to identify BRCA1-like
and BRCA2-like tumors among non-BRCA1/2 tumors in
a study by Joosse et al. using array-CGH profiles. In one
study, two out of 48 non-BRCA1/2 breast tumors exhib-
ited chromosomal aberration patterns similar to those
found in BRCA1-mutated tumors, of which hypermethy-
lation of the BRCA1 promoter was demonstrated in one
sample [30]. In another study focusing on BRCA2, 12
tumors out of 89 tumors were found to exhibit a high
level of similarity with BRCA2-mutated breast tumors
[31]. In two cases, additional indications of a dysfunc-
tional BRCA2 gene function were observed.
Promoter methylation
To find further evidence for BRCA1 or BRCA2 involve-
ment in the familial non-BRCA1/2 tumors, we performedmethylation-specific MLPA analysis of the BRCA1 and
BRCA2 promoter regions. Four non-BRCA1/2 samples
were found to be methylated in the BRCA1 promoter
region (3 basal-like, 1 normal-like). Notably, the three
basal-like tumors were all found also to have a BRCA1-
like expression profile. This supports the hypothesis that
tumors with epigenetic silencing of BRCA1 by promoter
hyper-methylation are similar to BRCA1 mutated tu-
mors [30,32-34]. The absence of BRCA2 promoter
methylation in our sample group is in line with previous
observations [35].
Aggregation of molecular subtypes within non-BRCA1/2
families
It is well established that families carrying a germline
BRCA1 mutation have increased incidence of basal-like/
triple-negative breast cancers, while germline BRCA2
mutations predispose to cancers of the lumB subtype
[22-24]. If the same tendency is true for defects in other
high penetrance breast cancer genes, tumors from gene-
tically related patients would exhibit related molecular
subtypes, as it is the case for BRCA1 and BRCA2 fa-
milies. The 70 familial non-BRCA1/2 cases included in
the current study, originated from 58 breast cancer
families with tumor material from one affected family
member and from 11 families with tumor material from
more than one affected individual. This gave us a unique
opportunity to investigate the “same gene – same subtype”
hypothesis. Convincingly, we found that members of the
same family shared the same tumor subtype in 8 of the 11
families. Three of the families were characterized by lumA
tumors only (including the 3-case family), three families
had lumB tumors, one had HER2-enriched tumors and
one had only basal-like tumors. By computer simulation
we found that the observed familial aggregation was highly
unlikely to be a chance observation.
In order to confirm our observations, we identified a
dataset from a study by Hedenfalk et al. where gene ex-
pression data were available from tumors from 5 high-risk
families negative for BRCA1/2 mutations [26]. Three
2-case families showed full concordance, while a 3-case
family contained 2 normal-like samples and 1 basal-like,
and another 3-case family was represented by 3 different
subtypes. Again, computer simulation confirmed this as
significantly different from random.
Our observations indicate an underlying common ge-
netic basis in these families and that the cancers in the
families are unlikely to be sporadic of origin. The family
members may carry an inherited susceptibility not just
to breast cancer but to a particular subtype of breast
cancer. In support of the “same gene – same subtype”
hypothesis, in a study by Waddell et al. the authors
noticed that all tumor biopsies from ATM mutation
carriers included in their study were classified as luminal
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family, four out of five family members were classified as
lumA. Furthermore, a study by Nagel et al. included a
group of 26 breast tumors from CHEK2 1100delC car-
riers; all were classified as luminal tumors (8 LumA and
18 LumB). On the contrary, a study analyzing tumors
using IHC noted that different tumors within the same
family frequently belonged to different phenotype cate-
gories [37]. This discrepancy may, however, be related to
differences in methodology and/or inclusion criteria. In
addition, in a recent study by Didraga et al., a specific
tumor arrayCGH profile has been shown to cluster
within a subgroup of non-BRCA1/2 families [38].
Segregation studies have indicated that the remaining
genetic susceptibility within non-BRCA1/2 families may
be explained by a mixture of rare high-risk variants and
polygenic mechanisms involving more common and/or
rare low-penetrance alleles or rare moderate penetrance
genes, acting in concert to confer a high breast cancer
risk. Our observations that family members often shares
the same molecular subtype may be compatible with both
scenarios. The cancer-risk and tumor subtype may be a
result of either private mutations in high-penetrance genes
or be a result of multiple low/moderate penetrant genes
acting in concert.
In our study, BRCA1 promoter methylation was de-
tected in breast tumors from both women in a family with
basal-like tumors (Family 031). Involvement of BRCA1
was further supported as both tumors were predicted to
be BRCA1-like by expression analysis. To investigate if
BRCA1 methylation could be due to an inherited trait in
this family we analyzed DNA from peripheral blood leu-
kocytes available from one of the women. No aberrant
BRCA1 methylation pattern in the blood sample was de-
tected by the MLPA method.
In the 3 pure lumB families, we found full concor-
dance in the BRCA2-like prediction results between
family members of the same family. Tumors from one
lumB family were classified as BRCA2-like, which could
indicate inactivation of BRCA2 or related genes. In two
other lumB families all members were classified as non-
BRCA2-like (sporadic-like), indicating that BRCA2 is less
likely to be involved in the development of cancer in
these families.
Conclusions
Familial non-BRCA1/2 breast tumors comprising a mo-
lecularly heterogeneous group of cancers can be further
classified by RNA profiling into subgroups showing high
resemblance to the intrinsic molecular subtypes. To the
best of our knowledge this is the first study to systemat-
ically demonstrate that members of the same family
often share the same molecular breast cancer subtype,
indicating that germline inactivation of certain genesmay give rise to specific breast cancer subtypes. These
findings could be highly relevant when analyzing data
from next generation sequencing of affected family
members. Although additional validation studies are re-
quired to confirm this tendency, our findings suggest
that future genetic analysis may benefit from stratifying
tumors/families into molecularly homogeneous subtypes
in order to identify new high penetrance susceptibility
genes.
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